Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancer
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000003680
- Lead Sponsor
- ippon Medical School Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Not provided
1)Uncontrolled infection or serious medical complications 2)massive pleural effusion or ascites(accept controrable pleural effusion with OK-432) 3)brain metastasis 4)history of severe cardiac disease 5)uncontrollable diabetes 6)recieving anticoagulant drug(except Aspirin under 324mg/day) 7)history of gross hemoptysis(>2.6ml) 8)history of severe hemosputum(over 1week, or reciving hemostatic drug) 9)uncontrollable hypertension 10)history of GI perfortion(within the last 1 year) 11)history of myocardial infarction or cerebral infarction 12)interstitial pneumonia or pulmonary fibrosis detectable on CT scan 13)history of drug-indused pneumonitis 14)the operation has been scheduled for the examination period 15)treatment history of Pemetrexed, Carboplatin, and Bevacizumab 16)severe drug allegy 17)not reciving folic acid and vitamin B12 18)active concomitant malignancy 19)history of severe mental disorder 20)now pregnant or lactation 21)judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate, feasibility
- Secondary Outcome Measures
Name Time Method safety,progression free survival,time to response,overall survival